Schizophrenia Drug Market & Pipeline Insight

Publish Date:- Jun-2014       No Of Pages (197)

Electronic Access - Single User License $1200 Buy Now
CD-ROM Mail Delivery $1500Buy Now
Hard Copy Mail Delivery $1800 Buy Now
Electronic Access - Multi-User License $2400 Buy Now


Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could possibly be affected by this disease. There have been rare cases of young children and adolescents also being affected. Overall, in most cases, the development of schizophrenia in earlier stages implies that the disease is very severe. Additionally, it has also been observed that schizophrenia is more severe in men than in women.

Though schizophrenia has been in the realm of research for over a century, the actual cause of the disorder still remains unknown. Pharmacological treatments have been in wide use for many years. However, there is hardly any evidence that these treatments have significantly improved outcomes for most people with schizophrenia. The pharmaceutical companies in this market are currently facing and are expected to continue to face stiff competition from many generic atypical antipsychotics. The major target of differentiating the products through improved treatment of negative or cognitive symptoms, partial responders, as well as improved tolerability, and demonstration of cost-effectiveness are essential have become the main focus of the pharma companies in this market.

The future years are likely to witness a shift in the way in which this disease is perceived. With schizophrenia being considered as a neuro developmental disorder with psychosis as a late stage of illness, it is likely that the current unsatisfactory outcomes could change. Such new ideas of looking into schizophrenia as a neuro developmental disorder, which is substantially different from the way it has been treated previously, offers much potential for future prevention and cure over the next two decades.

Schizophrenia Drug Market & Pipeline Insight” Report Highlights:

• Schizophrenia Drug Market Overview
• Marketed Drug Profiles & Patent Analysis
• Clinical Trial Insight by Phase & Country
• Drug in Clinical Development Phase: 143
• Majority Therapies in Preclinical Phase: 65
• Marketed Schizophrenia Drugs: 16
• Suspended & Discontinued Drug Profiles: 163
• Competitive Landscape


Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could possibly be affected by this disease. There have been rare cases of young children and adolescents also being affected. Overall, in most cases, the development of schizophrenia in earlier stages implies that the disease is very severe. Additionally, it has also been observed that schizophrenia is more severe in men than in women.

Though schizophrenia has been in the realm of research for over a century, the actual cause of the disorder still remains unknown. Pharmacological treatments have been in wide use for many years. However, there is hardly any evidence that these treatments have significantly improved outcomes for most people with schizophrenia. The pharmaceutical companies in this market are currently facing and are expected to continue to face stiff competition from many generic atypical antipsychotics. The major target of differentiating the products through improved treatment of negative or cognitive symptoms, partial responders, as well as improved tolerability, and demonstration of cost-effectiveness are essential have become the main focus of the pharma companies in this market.

The future years are likely to witness a shift in the way in which this disease is perceived. With schizophrenia being considered as a neuro developmental disorder with psychosis as a late stage of illness, it is likely that the current unsatisfactory outcomes could change. Such new ideas of looking into schizophrenia as a neuro developmental disorder, which is substantially different from the way it has been treated previously, offers much potential for future prevention and cure over the next two decades.

Schizophrenia Drug Market & Pipeline Insight” Report Highlights:

• Schizophrenia Drug Market Overview
• Marketed Drug Profiles & Patent Analysis
• Clinical Trial Insight by Phase & Country
• Drug in Clinical Development Phase: 143
• Majority Therapies in Preclinical Phase: 65
• Marketed Schizophrenia Drugs: 16
• Suspended & Discontinued Drug Profiles: 163
• Competitive Landscape

1. Schizophrenia Drug Market Overview
  1.1 Market Overview
  1.2 Clinical Insight

2. Schizophrenia Drugs Clinical Pipeline by Phase & Country
  2.1 Unknown Phase
  2.2 Research
  2.3 Preclinical
  2.4 Clinical
  2.5 Phase I
  2.6 Phase I/II
  2.7 Phase II
  2.8 Phase II/III
  2.9 Phase III
  2.10 Preregistration

3. Marketed Schizophrenia Drugs Clinical Insight & Patent Analysis

4. Suspended & Discontinued Schizophrenia Drug Profile
  4.1 No Development Reported
  4.2 Discontinued
  4.3 Suspended

5. Competitive Landscape
  5.1 Abbott Laboratories
  5.2 Addex Pharmaceuticals
  5.3 Astellas Pharma
  5.4 Dainippon Sumitomo Pharma
  5.5 Eli Lilly
  5.6 GlaxoSmithKline
  5.7 Johnson & Johnson
  5.8 Merck
  5.9 Pfizer
  5.10 Roche
  5.11 Sanofi

Figure 1-1: Schizophrenia Drug Market (US$ Billion), 2013-2020
Figure 1-2: Schizophrenia Treatment Process in Future
Figure 1-3: Schizophrenia Drug Clinical Pipeline by Phase (%), 2014
Figure 1-4: Schizophrenia Drug Clinical Pipeline by Phase (Number), 2014
Figure 1-5: No Development Reported in Schizophrenia Drug Clinical Pipeline by Phase (%), 2014
Figure 1-6: No Development Reported in Schizophrenia Drug Clinical Pipeline by Phase (Number), 2014
Figure 1-7: Discontinued Schizophrenia Drug Clinical Pipeline by Phase (%), 2014
Figure 1-8: Discontinued Schizophrenia Drug Clinical Pipeline by Phase (Number), 2014
Figure 1-9: Suspended Schizophrenia Drug Clinical Pipeline by Phase (%), 2014
Figure 1-10: Suspended Schizophrenia Drug Clinical Pipeline by Phase (Number), 2014

List of Tables


Following Information For Each Drug Profile in Covered in More than 200 Tables in Report:


• Drug Profile Overview
• Active Indication
• Phase of Development
• Country for Clinical Trial
• Owner / Originator/ Licensee/Collaborator
• Administrative Route
• Drug Class


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC Code

• Designated Brand Name